What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-12-13 compared with 2023-03-09 · 60 added, 35 removed, 15 unchanged (86% of the section changed)

2 unchanged sentences

Market for our Common Stock

Our common stock is quoted on the NYSE American under the symbol “PLAG”.

Our common stock is quoted on the NYSE American under the

symbol “PLAG”.

Approximate Number of Holders of Our Common Stock

As of March 29, 2022, there were 346 stockholders of record of our

common stock.

As of December 31, 2023, there were 322 stockholders

of record of our common stock.

This does not include the holders whose shares are held in a depository trust in “street” name.

We have not declared or paid cash dividends other than the payment

of a dividend in April 2007 in connection with our reverse merger.

Any future decisions regarding dividends will be made by our Board

of Directors.

We currently intend to retain and use any future earnings for the development and expansion of our business and do not

anticipate paying any cash dividends in the foreseeable future.

We have not declared or paid cash dividends other

than the payment of a dividend in April 2007 in connection with our reverse merger.

Any future decisions regarding dividends will be made

by our Board of Directors.

We currently intend to retain and use any future earnings for the development and expansion of our business

and do not anticipate paying any cash dividends in the foreseeable future.

Issuances of Unregistered Securities

On May 9, 2019, we and Shanghai Xunyang entered into a share exchange

agreement with Xianning Bozhuang and each of the original shareholders of Xianning Bozhuang.

Such transaction closed on May 14, 2019.

Pursuant to the share exchange agreement, we issued an aggregate of 1,080,000 shares of common stock of the Company to the Sellers in

exchange for the transfer of all of the equity interest of Xianning Bozhuang to Shanghai Xunyang.

On June 17, 2019, the Company entered into a securities purchase agreement,

pursuant to which five individuals residing in the PRC agreed to purchase an aggregate of 1,300,000 shares of the Company’s common

stock, par value $0.001 per share, for an aggregate purchase price of $5,460,000, representing a purchase price of $4.20 per share.

transaction closed on June 19, 2019.

On January 26, 2021, the Company entered into a securities purchase

agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 2,700,000 shares of the Company’s

common stock, par value $0.001 per share, for an aggregate purchase price of $6,750,000, representing a purchase price of $2.50 per share.

On May 9, 2019, we and Shanghai Xunyang entered

into a share exchange agreement with Xianning Bozhuang and each of the original shareholders of Xianning Bozhuang.

Such transaction closed

on May 14, 2019.

Pursuant to the share exchange agreement, we issued an aggregate of 1,080,000 shares of common stock of the Company to

the Sellers in exchange for the transfer of all of the equity interest of Xianning Bozhuang to Shanghai Xunyang.

On June 17, 2019, the Company entered into a securities

purchase agreement, pursuant to which five individuals residing in the PRC agreed to purchase an aggregate of 1,300,000 shares of the

Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $5,460,000, representing a purchase price

of $4.20 per share.

The transaction closed on June 19, 2019.

On January 26, 2021, the Company entered into a

securities purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 2,700,000 shares

of the Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $6,750,000, representing a purchase

price of $2.50 per share.

The transaction closed on January 29, 2021.

On March 9, 2021, the Company entered into a share exchange agreement

with Jilin Chuangyuan and each of the original shareholders of Jilin Chuangyuan.

Pursuant to the share exchange agreement, we issued

an aggregate of 3,300,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 75% of the equity interest

of Jilin Chuangyuan.

On April 24, 2021, the Company entered into a securities purchase

agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 4,000,000 shares of the Company’s

common stock, par value $0.001 per share, for an aggregate purchase price of $7,600,000, representing a purchase price of $1.90 per share.

On March 9, 2021, the Company entered into a share

exchange agreement with Jilin Chuangyuan and each of the original shareholders of Jilin Chuangyuan.

Pursuant to the share exchange agreement,

we issued an aggregate of 3,300,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 75% of the equity

interest of Jilin Chuangyuan.

On April 24, 2021, the Company entered into a securities

purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 4,000,000 shares of the

Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $7,600,000, representing a purchase price

of $1.90 per share.

The transaction closed on May 20, 2021.

On July 15, 2021, the Company entered into a share exchange agreement

with Anhui Ansheng and each of the original shareholders of Anhui Ansheng.

Pursuant to the share exchange agreement, we issued an aggregate

of 4,800,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 66% of the equity interest of Anhui

On July 15, 2021, the Company entered into a share

exchange agreement with Anhui Ansheng and each of the original shareholders of Anhui Ansheng.

Pursuant to the share exchange agreement,

we issued an aggregate of 4,800,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 66% of the equity

interest of Anhui Ansheng.

On December 9, 2021, the Company entered into a

3 unchanged sentences

of the equity interest of Shandong Yunchu.

On January 13, 2022, the Company entered into a

securities purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 7,000,000 shares

of the Company’s common stock for an aggregate purchase price of $7,000,000, representing a purchase price of $1.00 per share.

transaction closed on January 14, 2022.

On April 8, 2022, the Company enterted into a share

exchange agreement with Allinyson and each of the orginial shareholders of Allinyson.

including its wholly-owned subsidiary Baokuan Technology

(Hongkong) Limited.Pursuant to the share exchange agreement, we issued an aggregate of 7,500,000 shares of common stock of the Company

to the Sellers in exchange for the transfer of all of the equity interest of Allinyson.

On May 19, 2022, the Company entered into a Securities

Purchase Agreement with two investors residing in the People’s Republic of China, pursuant to which the purchasers agreed to invest

an aggregate of $4,100,000 in the Company in exchange for an aggregate of 10,000,000 shares of the Company’s common stock, representing

a purchase price of $0.41 per share.

The transaction closed on May 27, 2022.

On July 15, 2022, the Company enerted into a share

exchange agreement with Xiangtian Energy and the the shareholder of Xiantian Energy.

Pursuant to the Share Exchange Agreement, in exchange

for the acquisition of the 30% equity interest of Xiangtian Energy, the Company issued an aggregate of 12,000,000 shares of common stock,

par value $0.001 per share, of the Company to the Seller.

Securities Authorized for Issuance under Equity Compensation

We have issue 870,000 shares under our equity compensation plan in

the fiscal year of 2021.

We did not issue any shares under our equity compensation

plan in the fiscal year of 2023.

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K/A

Item 5. Market for Registrant’s Common Equity